Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's disease patients

被引:13
作者
Mueller, Thomas [1 ,2 ]
Muhlack, Siegfried [2 ]
机构
[1] St Joseph Hosp Berlin Weissensee, Dept Neurol, D-13088 Berlin, Germany
[2] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, D-44791 Bochum, Germany
关键词
Cysteinyl-glycine; Cysteine; Oxidative stress; Parkinson's disease; COENZYME Q(10); L-DOPA; PROGRESSION; GLUTATHIONE; PRAMIPEXOLE; PHARMACOKINETICS; METABOLISM; TRIAL;
D O I
10.1007/s00702-013-1155-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Oxidative stress is influenced by the thiol homeostasis, which regulates the redox milieu via glutathione. Components of glutathione metabolism are cysteine and cysteinyl-glycine. Both substrates decay following levodopa application or dopamine-related oxidative stress. Objective was to investigate the impact of an acute levodopa application with and without catechol-O-methyltransferase inhibitor on cysteine- and cysteinyl-glycine plasma levels. On two investigation days, 13 patients with Parkinson's disease took one retarded release 200-mg levodopa/50 mg carbidopa-containing tablet or one 150-mg levodopa/50-mg carbidopa/200-mg entacapone formulation under standardized conditions. Levodopa, 3-O-methyldopa, cysteine and cysteinyl-glycine were measured at baseline, 80 and 140 min following levodopa administration. Cysteine and cysteinyl-glycine similarly decreased, levodopa was nearly equal during both conditions. Entacapone lowered 3-O-methyldopa. Cysteine decay may be due to an elevated glutathione generation, which consumes cysteine. Cysteinyl-glycine decrease results from the alternative glutathione transformation to its oxidized form glutathione dissulfide after free radical scavenging.
引用
收藏
页码:643 / 648
页数:6
相关论文
共 26 条
[1]   Dopamine but not L-dopa stimulates neural glutathione metabolism. Potential implications for Parkinson's and other dopamine deficiency states [J].
Allen, George F. G. ;
Ullah, Yasmin ;
Hargreaves, Iain P. ;
Land, John M. ;
Heales, Simon J. R. .
NEUROCHEMISTRY INTERNATIONAL, 2013, 62 (05) :684-694
[2]  
Fahn S, 2004, NEW ENGL J MED, V351, P2498
[3]   Pramipexole protects against H2O2-induced PC12 cell death [J].
Fujita, Y ;
Izawa, Y ;
Ali, N ;
Kanematsu, Y ;
Tsuchiya, K ;
Hamano, S ;
Tamaki, T ;
Yoshizumi, M .
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 372 (04) :257-266
[4]   Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice [J].
Inden, Masatoshi ;
Kitamura, Yoshihisa ;
Tamaki, Aya ;
Yanagida, Takashi ;
Shibaike, Tomonori ;
Yamamoto, Atsuko ;
Takata, Kazuyuki ;
Yasui, Hiroyuki ;
Taira, Takahiro ;
Ariga, Hiroyoshi ;
Taniguchi, Takashi .
NEUROCHEMISTRY INTERNATIONAL, 2009, 55 (08) :760-767
[5]   Neuropathy in Parkinson's Disease Patients with Intestinal Levodopa Infusion versus Oral Drugs [J].
Jugel, Constanze ;
Ehlen, Felicitas ;
Taskin, Birol ;
Marzinzik, Frank ;
Mueller, Thomas ;
Klostermann, Fabian .
PLOS ONE, 2013, 8 (06)
[6]  
Kieburtz K, 2007, NEUROLOGY, V68, P20
[7]  
Marek K, 2002, JAMA-J AM MED ASSOC, V287, P1653
[8]   A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), α-tocopherol was ineffective in the DATATOP study [J].
Miklya, I ;
Knoll, B ;
Knoll, J .
LIFE SCIENCES, 2003, 72 (23) :2641-2648
[9]   Effect of L-Dopa and the catechol-O-methyltransferase inhibitor Ro 41-0960 on sulfur amino acid metabolites in rats [J].
Miller, JW ;
ShukittHale, B ;
VillalobosMolina, R ;
Nadeau, MR ;
Selhub, J ;
Joseph, JA .
CLINICAL NEUROPHARMACOLOGY, 1997, 20 (01) :55-66
[10]   Comparison of 200 mg retarded release levodopa/carbidopa -: with 150 mg levodopa/carbidopa/entacapone application:: pharmacokinetics and efficacy in patients with Parkinson's disease [J].
Mueller, T. ;
Ander, L. ;
Kolf, K. ;
Woitalla, D. ;
Muhlack, S. .
JOURNAL OF NEURAL TRANSMISSION, 2007, 114 (11) :1457-1462